Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fraser Cunningham

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Parasitology|June 18, 2013
An in silico structure-based approach to anti-infective drug discoveryFraser Cunningham, Martin J McPhillie, A Peter Johnson, et al.
ACS Infectious Diseases|July 16, 2025
AI Drug Discovery: Expanding the Horizons of Infectious Disease TherapeuticsMarta Bon, Fraser Cunningham, Jyoti Chauhan, et al.
SLAS Technology|March 16, 2026
Experience from an HTS campaign: Investigation of susceptibility and rescue of SARS-CoV-2 nsp3 protease assay from metal contaminationIrene Georgiou, Sandra O'Neill, Colin Robinson, et al.
European Journal of Medicinal Chemistry|October 22, 2016
Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activityEleni Pitta, Olga Balabon, Maciej K Rogacki, et al.
Antimicrobial Agents and Chemotherapy|July 23, 2014
Pantothenic acid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapySarmad N Mageed, Fraser Cunningham, Alvin Wei Hung, et al.
Plos One|April 20, 2017
Design, synthesis and structure-activity relationship study of wollamide B; a new potential anti TB agentHenok Asfaw, Katja Laqua, Anna Maria Walkowska, et al.
Frontiers in Pharmacology|May 6, 2022
Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement TherapiesLoveleena Bansal, Eva-Maria Nichols, Daniel P Howsmon, et al.
Journal of Medicinal Chemistry|May 25, 2012
Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenasesPaul T P Bedingfield, Deborah Cowen, Paul Acklam, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2017
Interconvertible geometric isomers of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors exhibit multiple binding modesGlenn A McConkey, Paul T P Bedingfield, David R Burrell, et al.
Scientific Reports|September 29, 2016
Repurposing clinically approved cephalosporins for tuberculosis therapySantiago Ramón-García, Rubén González Del Río, Angel Santos Villarejo, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Parasitology|June 18, 2013
An in silico structure-based approach to anti-infective drug discoveryFraser Cunningham, Martin J McPhillie, A Peter Johnson, et al.
ACS Infectious Diseases|July 16, 2025
AI Drug Discovery: Expanding the Horizons of Infectious Disease TherapeuticsMarta Bon, Fraser Cunningham, Jyoti Chauhan, et al.
SLAS Technology|March 16, 2026
Experience from an HTS campaign: Investigation of susceptibility and rescue of SARS-CoV-2 nsp3 protease assay from metal contaminationIrene Georgiou, Sandra O'Neill, Colin Robinson, et al.
European Journal of Medicinal Chemistry|October 22, 2016
Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activityEleni Pitta, Olga Balabon, Maciej K Rogacki, et al.
Antimicrobial Agents and Chemotherapy|July 23, 2014
Pantothenic acid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapySarmad N Mageed, Fraser Cunningham, Alvin Wei Hung, et al.
Plos One|April 20, 2017
Design, synthesis and structure-activity relationship study of wollamide B; a new potential anti TB agentHenok Asfaw, Katja Laqua, Anna Maria Walkowska, et al.
Frontiers in Pharmacology|May 6, 2022
Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement TherapiesLoveleena Bansal, Eva-Maria Nichols, Daniel P Howsmon, et al.
Journal of Medicinal Chemistry|May 25, 2012
Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenasesPaul T P Bedingfield, Deborah Cowen, Paul Acklam, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2017
Interconvertible geometric isomers of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors exhibit multiple binding modesGlenn A McConkey, Paul T P Bedingfield, David R Burrell, et al.
Scientific Reports|September 29, 2016
Repurposing clinically approved cephalosporins for tuberculosis therapySantiago Ramón-García, Rubén González Del Río, Angel Santos Villarejo, et al.
Pageof 3